Key result
Iloprost gains FDA approval for severe frostbite and shows potential in various vascular conditions.
Why the study?
Following its approval for pulmonary arterial hypertension and subsequent use in other vascular conditions, iloprost was newly approved for severe frostbite.
This review summarizes the pharmacologic properties and clinical applications of iloprost, including its recent FDA approval for severe frostbite alongside established uses in pulmonary arterial hypertension and other vascular conditions.
Answers are grounded in this paper and cite their sources.
May expand frostbite treatment options; leaves open efficacy in other vascular conditions.
Iloprost is a synthetic long-acting prostacyclin-analog drug used to treat various vascular diseases. The Federal Drug Administration approved the drug in 2004 for pulmonary arterial hypertension, and it has since been shown to be helpful in other vascular conditions such as scleroderma and Raynaud phenomenon. The Federal Drug Administration has now approved the use of iloprost for severe frostbite. This review summarizes the pharmacologic properties of iloprost, its clinical applications, and potential therapeutic benefits in vascular conditions.
No takes yet. Share an insight, caveat, or question.
Banerji et al. (2025) conducted a review in Vascular diseases. Iloprost was evaluated. Iloprost, a synthetic prostacyclin-analog, has been approved by the FDA for severe frostbite and offers potential therapeutic benefits in various vascular conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: